Granulomatous amoebic encephalitis medical therapy

Granulomatous amoebic encephalitis Microchapters
Home
Patient Information
Overview
Pathophysiology
Causes
Differentiating Granulomatous amoebic encephalitis from other Diseases
Epidemiology and Demographics
Risk Factors
Natural history, Complications, and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Primary Prevention
Case Studies
Case #1
Granulomatous amoebic encephalitis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Granulomatous amoebic encephalitis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Granulomatous amoebic encephalitis medical therapy
CDC on Granulomatous amoebic encephalitis medical therapy
Granulomatous amoebic encephalitis medical therapy in the news
Blogs on Granulomatous amoebic encephalitis medical therapy
Directions to Hospitals Treating Granulomatous amoebic encephalitis
Risk calculators and risk factors for Granulomatous amoebic encephalitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

GAE can, in general, must be treated by killing the pathogenic amoebas which cause it. Even with treatment, the condition is often fatal, and there are very few recorded survivors, almost all of whom suffered permanent neurocognitive deficits. Several drugs have been shown to be effective against GAE-causing organisms in vitro.

Medical Therapy

Although there have been more than 200 cases of Balamuthia infection worldwide, few patients are known to have survived as a result of successful drug treatment[1,2]. Early diagnosis and treatment might increase the chances for survival[3].

Drugs used in treating Granulomatous Amebic Encephalitis (GAE) caused by Balamuthia have included a combination of flucytosine, pentamidine, fluconazole, sulfadiazine and either azithromycin or clarithromycin[1,2,4,5]. Recently, miltefosine in combination with some of these other drugs has shown some promise[2]. Much more information is needed in treating patients with GAE due to Balamuthia.

References

1) Perez MT, Bush LM. Balamuthia mandrillaris amebic encephalitis. Curr Infect Dis Rep. Jul 2007;9(4):323-328. 2) Martinez DY, Seas C, Bravo F, et al. Successful treatment of Balamuthia mandrillaris amoebic infection with extensive neurological and cutaneous involvement. Clin Infect Dis. Jul 15 2010;51(2):e7-11. 3) Siddiqui R, Khan NA. Balamuthia amoebic encephalitis: an emerging disease with fatal consequences. Microb Pathog. Feb 2008;44(2):89-97. 4) Cary LC, Maul E, Potter C, et al. Balamuthia mandrillaris meningoencephalitis: survival of a pediatric patient. Pediatrics. Mar 2010;125(3):e699-703. 5) Drugs for Parasitic Infections: The Medical Letter; 2010.

Template:WikiDoc Sources